141 related articles for article (PubMed ID: 28830934)
21. Notch-1 signaling activates NF-κB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway.
Li L; Zhang J; Xiong N; Li S; Chen Y; Yang H; Wu C; Zeng H; Liu Y
Med Oncol; 2016 Apr; 33(4):33. PubMed ID: 26945854
[TBL] [Abstract][Full Text] [Related]
22. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
23. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
24. Chronic peripheral hyperinsulinemia has no substantial influence on tau phosphorylation in vivo.
Becker K; Freude S; Zemva J; Stöhr O; Krone W; Schubert M
Neurosci Lett; 2012 May; 516(2):306-10. PubMed ID: 22521314
[TBL] [Abstract][Full Text] [Related]
25. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
26. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
27. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
[TBL] [Abstract][Full Text] [Related]
28. STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells.
Nan H; Han L; Ma J; Yang C; Su R; He J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1684-1692. PubMed ID: 29408595
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
Li P; Zhang Q; Torossian A; Li ZB; Xu WC; Lu B; Fu S
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e391-7. PubMed ID: 22414288
[TBL] [Abstract][Full Text] [Related]
30. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
[TBL] [Abstract][Full Text] [Related]
31. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Wysocki PJ; Wierusz-Wysocka B
Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
[TBL] [Abstract][Full Text] [Related]
32. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
34. Metabolic reprogramming in type 2 diabetes and the development of breast cancer.
Martin SD; McGee SL
J Endocrinol; 2018 May; 237(2):R35-R46. PubMed ID: 29487204
[TBL] [Abstract][Full Text] [Related]
35. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer.
Vona-Davis L; Howard-McNatt M; Rose DP
Obes Rev; 2007 Sep; 8(5):395-408. PubMed ID: 17716297
[TBL] [Abstract][Full Text] [Related]
36. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
[TBL] [Abstract][Full Text] [Related]
37. Insulin inhibits IL-10-mediated regulatory T cell function: implications for obesity.
Han JM; Patterson SJ; Speck M; Ehses JA; Levings MK
J Immunol; 2014 Jan; 192(2):623-9. PubMed ID: 24323581
[TBL] [Abstract][Full Text] [Related]
38. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
39. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
40. A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Schech A; Yu S; Goloubeva O; McLenithan J; Sabnis G
Endocr Relat Cancer; 2015 Aug; 22(4):645-56. PubMed ID: 26113604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
